Toward fulfilling the promise of molecular medicine in fragile X syndrome

Area of Science:

• Neuroscience
• Genetics
• Developmental Biology

Background:

• Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability and a primary genetic contributor to autism spectrum disorder.
• FXS pathogenesis is linked to the absence of the fragile X mental retardation protein (FMRP), an RNA-binding protein critical for regulating protein synthesis.
• Altered synaptic function in FXS neurons involves dysregulated protein synthesis downstream of group 1 metabotropic glutamate receptors (Gp1 mGluRs).

Purpose of the Study:

• To investigate the role of FMRP in regulating synaptic protein synthesis.
• To explore the therapeutic potential of targeting Gp1 mGluRs, particularly mGluR5, for FXS.
• To establish a framework for developing targeted treatments for neurodevelopmental disorders.

Main Methods:

• Review of existing evidence on FMRP function and synaptic plasticity.
• Analysis of studies investigating Gp1 mGluR signaling in FXS models.
• Examination of preclinical data on mGluR5 inhibition in FXS animal models.

Main Results:

• Loss of FMRP leads to exaggerated protein synthesis upon Gp1 mGluR activation.
• Inhibition of mGluR5 signaling effectively corrects aberrant phenotypes in FXS animal models.
• This therapeutic strategy is progressing to human clinical trials.

Conclusions:

• Exaggerated protein synthesis downstream of Gp1 mGluRs is a key pathogenic mechanism in FXS.
• Targeting mGluR5 represents a promising therapeutic avenue for FXS.
• FXS serves as a model for developing gene-to-treatment strategies for neurodevelopmental disorders, potentially informing autism research.